Survival of patients with localized prostate cancer treated with percutaneous transperineal placement of radioactive gold seeds: stages A2, B, and C.
Between 1984 and 1991, a total of 177 patients with adenocarcinoma of the prostate were treated with transcutaneous, transperineal radioactive gold seeds. Of these 177 patients, 20 were determined to have pelvic lymph node involvement and were excluded from this review. The remaining 157 patients received a median radioactivity dose of 164 mCi with a median follow-up of 48 months. Cancer-specific survival at 5 years was 100% for stage A2 and B1, 90% for stage B2, and 76% for stage C cancer. Covariates of grade, total radioactivity administered, age of the patient, and number of seeds implanted did not influence disease-free survival in a statistically significant manner. Significant complications were observed in two patients. The survival rates of patients treated with 198Au seed implantation for localized cancer are equivalent or better when compared to historical data of patients treated with 125I implantation, external beam radiotherapy, combination radioactive gold seed implantation and external irradiation, and radical prostatectomy. In addition, these comparable survival rates using interstitial 198Au seeds may be achieved with less morbidity.
Hochstetler
J A
JA
Department of Urology, University of Iowa Hospitals and Clinics, Iowa-City 52242-1089, USA.
Kreder
K J
KJ
Brown
C K
CK
Loening
S A
SA
D000206:Actuarial Analysis; D000368:Aged; D001918:Brachytherapy / Q000379:methods; D004307:Dose-Response Relationship, Radiation; D005500:Follow-Up Studies; D006050:Gold Radioisotopes / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D010502:Perineum; D011471:Prostatic Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D016019:Survival Analysis; D016896:Treatment Outcome
D006050:Gold Radioisotopes